Back
  1. Home
  2. Profile of Aurélie Henry (ULiège)
Profil

Henry Aurélie

See author's contact details
Main Referenced Co-authors
Bellahcene, Akeila  (6)
Castronovo, Vincenzo  (6)
Goffart, Nicolas  (5)
Peulen, Olivier  (5)
Rogister, Bernard  (5)
Main Referenced Keywords
Glioblastoma (2); glioblastome (2); ostéopontine (2); radiorésistance (2); Allogeneic (1);
Main Referenced Unit & Research Centers
Giga-Cancer - ULiège [BE] (1)
Laboratoire de recherche sur les métastases (1)
Main Referenced Disciplines
Oncology (7)
Immunology & infectious disease (2)
Hematology (1)
Neurology (1)
Biochemistry, biophysics & molecular biology (1)

Publications (total 11)

The most downloaded
288 downloads
Lamour, V., Nokin, M.-J., Henry, A., Castronovo, V., & Bellahcene, A. (2013). Les proteines SIBLING - Outils moleculaires de la progression tumorale et de l'angiogenese. MS. Medecine Sciences, 29 (11), 1018-25. doi:10.1051/medsci/20132911019 https://hdl.handle.net/2268/165469

The most cited

44 citations (Scopus®)

Lamour, V., Henry, A., Kroonen, J., Nokin, M.-J., von Marschall, Z., Fisher, L., Chau, T.-L., Chariot, A., Sanson, M., Delattre, J.-Y., Turtoi, A., Peulen, O., Rogister, B., Castronovo, V., & Bellahcene, A. (2015). Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. International Journal of Cancer. doi:10.1002/ijc.29454 https://hdl.handle.net/2268/178910

Tan, A. K., Henry, A., Goffart, N., van Logtestijn, S., Bours, V., Hol, E. M., & Robe, P. (2024). Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma. Cancers, 16 (1), 193. doi:10.3390/cancers16010193
Peer Reviewed verified by ORBi

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (11 April 2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40 (4), 335-337. doi:10.1016/j.ccell.2022.02.005
Peer Reviewed verified by ORBi

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3
Peer reviewed
* These authors have contributed equally to this work.

DUBOIS, N., Berendsen, S., HENRY, A., Nguyen, M., Bours, V., & Robe, P. A. (26 February 2018). I-Kappa-B kinase-epsilon activates nuclear factor-kappa B and STAT5B and supports glioblastoma growth but amlexanox shows little therapeutic potential in these tumors. Cancer Translational Medicine, 4 (1), 1-8. doi:10.4103/ctm.ctm_3_18
Peer Reviewed verified by ORBi

Henry, A., Nokin, M.-J., Leroi, N., Lallemand, F., Lambert, J., Goffart, N., RONCARATI, P., BIANCHI, E., Peixoto, P., Blomme, A., Turtoi, A., Peulen, O., Habraken, Y., Scholtes, F., Martinive, P., Delvenne, P., Rogister, B., Castronovo, V., & Bellahcene, A. (2016). New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget. doi:10.18632/oncotarget.11483
Peer Reviewed verified by ORBi

Henry, A. (2016). Rôle de l'ostéopontine dans la progression et la radiorésistance des glioblastomes humains [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/315359

Henry, A., Nokin, M.-J., Leroi, N., LALLEMAND, F., Lambert, J., Goffart, N., Peixoto, P., Blomme, A., BIANCHI, E., Habraken, Y., RONCARATI, P., Peulen, O., SCHOLTES, F., MARTINIVE, P., Rogister, B., Delvenne, P., Turtoi, A., Castronovo, V., & Bellahcene, A. (22 March 2016). Osteopontin predicts radiotherapy response of glioblastoma patients : new role in DNA damage repair [Paper presentation]. 3rd Symposium on small animal precision image-guided radiotherapy, Gand, Belgium.

Peixoto, P.* , Blomme, A.* , Costanza, B.* , Ronca, R., Rezzola, S., Palacios, A., SCHOYSMAN, L., Boutry, S., Goffart, N., Peulen, O., Maris, P., Di Valentin, E., Hennequière, V., BIANCHI, E., Henry, A., Meunier, P., Rogister, B., MULLER, R., Delvenne, P., ... Turtoi, A. (2016). HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. Oncogene. doi:10.1038/onc.2015.506
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Henry, A., Bellahcene, A., Castronovo, V., Peixoto, P., Goffart, N., Lallemand, F., Leroi, N., Peulen, O., MARTINIVE, P., Habraken, Y., Turtoi, A., Rogister, B., & Blomme, A. (Other coll.). (10 September 2015). Osteopontin as a new target in glioblastoma progression and resistance to radiotherapy [Paper presentation]. II International Symposium on clinical and basic investigation in glioblastoma, Toledo, Spain.

Lamour, V., Henry, A., Kroonen, J., Nokin, M.-J., von Marschall, Z., Fisher, L., Chau, T.-L., Chariot, A., Sanson, M., Delattre, J.-Y., Turtoi, A., Peulen, O., Rogister, B., Castronovo, V., & Bellahcene, A. (2015). Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. International Journal of Cancer. doi:10.1002/ijc.29454
Peer Reviewed verified by ORBi

Lamour, V., Nokin, M.-J., Henry, A., Castronovo, V., & Bellahcene, A. (2013). Les proteines SIBLING - Outils moleculaires de la progression tumorale et de l'angiogenese. MS. Medecine Sciences, 29 (11), 1018-25. doi:10.1051/medsci/20132911019
Peer Reviewed verified by ORBi

Contact ORBi